Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells 33,356 Shares of Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Orbimed Advisors Llc sold 33,356 shares of the business’s stock in a transaction on Wednesday, December 24th. The shares were sold at an average price of $44.55, for a total value of $1,486,009.80. Following the transaction, the director owned 3,561,655 shares of the company’s stock, valued at approximately $158,671,730.25. The trade was a 0.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Orbimed Advisors Llc also recently made the following trade(s):

• On Friday, December 19th, Orbimed Advisors Llc sold 875 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.49, for a total value of $38,928.75.
• On Thursday, December 18th, Orbimed Advisors Llc sold 100 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.49, for a total transaction of $4,449.00.
• On Wednesday, December 17th, Orbimed Advisors Llc sold 900 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.50, for a total transaction of $40,050.00.
• On Wednesday, November 26th, Orbimed Advisors Llc sold 1,600 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.49, for a total transaction of $71,184.00.
• On Tuesday, November 25th, Orbimed Advisors Llc sold 11,890 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.60, for a total transaction of $530,294.00.
• On Monday, November 24th, Orbimed Advisors Llc sold 94,583 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.54, for a total transaction of $4,212,726.82.

Sionna Therapeutics Stock Down 2.0%

NASDAQ:SION traded down $0.89 during midday trading on Monday, hitting $42.81. The stock had a trading volume of 133,694 shares, compared to its average volume of 339,078. Sionna Therapeutics, Inc. has a one year low of $7.26 and a one year high of $45.00. The stock has a 50-day moving average of $40.05 and a 200 day moving average of $28.35.

Sionna Therapeutics (NASDAQ:SION) last issued its earnings results on Wednesday, November 5th. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.06.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on SION shares. Jones Trading started coverage on shares of Sionna Therapeutics in a report on Monday, September 8th. They issued a “buy” rating and a $46.00 price target for the company. Raymond James Financial reissued a “strong-buy” rating on shares of Sionna Therapeutics in a report on Wednesday, November 5th. Royal Bank Of Canada reissued an “underperform” rating and issued a $24.00 price objective on shares of Sionna Therapeutics in a research note on Monday, December 1st. Wall Street Zen raised Sionna Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sionna Therapeutics in a report on Monday, December 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Sionna Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $43.14.

Institutional Trading of Sionna Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of America Corp DE lifted its holdings in shares of Sionna Therapeutics by 8.8% during the third quarter. Bank of America Corp DE now owns 6,541 shares of the company’s stock worth $192,000 after purchasing an additional 529 shares during the period. BNP Paribas Financial Markets increased its holdings in Sionna Therapeutics by 35.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,380 shares of the company’s stock worth $70,000 after buying an additional 619 shares during the period. Russell Investments Group Ltd. purchased a new position in Sionna Therapeutics during the 3rd quarter worth approximately $30,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in Sionna Therapeutics during the 2nd quarter valued at approximately $45,000. Finally, The Manufacturers Life Insurance Company lifted its stake in Sionna Therapeutics by 13.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,038 shares of the company’s stock valued at $660,000 after acquiring an additional 4,489 shares during the period.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.